Full history for every metric is available with a Kvantra account
Quantumzyme Corp. (QTZM)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | - | 0 | 0 |
| Operating profit | $m | -0 | -0 | |||||
| Net profit | $m | - | - | - | - | - | -0 | - |
| EPS reported | $ | -0.01 | - | |||||
| Operating cashflow per share | $ | -0.00 | -0.00 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.00 | -0.00 | |||||
| Free cash flow | $m | -0 | -0 | |||||
| Net debt | $m | 0 | 0 | |||||
| Book value equity | $m | -0 | -0 | |||||
| Book value per share | $ | -0.01 | -0.01 | |||||
| Number of shares | m | 35.12 | 35.33 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -23.91 | -70.32 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -84.16 | -495.13 | |||||
| EV/EBITDA LTM | x | -60.57 | -526.66 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -1.89% | -15.82% | |||||
| FCF Yield | % | -1.19% | -0.20% | |||||
| Quality | ||||||||
| ROE | % | 45.21% | 997.31% | |||||
| ROIC | % | 94.21% | 62.54% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.50 | -0.25 | |||||
| Net Debt/EBITDA | x | -1.40 | -2.09 | |||||
| EBIT/Net interest | x | -8.50 | 8.84 | |||||
| Net debt/market cap | % | 2.36% | 0.81% | |||||
| Net debt/Equity | x | -0.56 | -0.57 | |||||
| Gross debt/equity | x | -0.57 | -0.57 | |||||
Company overview
Quantumzyme Corp. is a biotransformation firm specializing in the creation of engineered enzymes, primarily utilized for the production of active pharmaceutical ingredients (APIs). Established in 2015, the company was formerly known as Reliant Services, Inc. until it rebranded as Quantumzyme Corp. in March 2023. Its operations are headquartered in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Quantumzyme Corp. (QTZM)
Quantumzyme Corp. is a biotransformation firm specializing in the creation of engineered enzymes, primarily utilized for the production of active pharmaceutical ingredients (APIs). Established in 2015, the company was formerly known as Reliant Services, Inc. until it rebranded as Quantumzyme Corp. in March 2023. Its operations are headquartered in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free